While Inovio Pharmaceuticals Inc has overperformed by 14.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INO fell by -1.49%, with highs and lows ranging from $14.75 to $3.89, whereas the simple moving average jumped by 66.42% in the last 200 days.
On January 25, 2024, Oppenheimer Upgraded Inovio Pharmaceuticals Inc (NASDAQ: INO) to Outperform. A report published by Maxim Group on November 09, 2022, Downgraded its rating to ‘Hold’ for INO. BofA Securities also Downgraded INO shares as ‘Underperform’, setting a target price of $2 on the company’s shares in a report dated November 01, 2022. RBC Capital Mkts Initiated an Sector Perform rating on July 19, 2022, and assigned a price target of $4. Oppenheimer May 11, 2022d its ‘Outperform’ rating to ‘Perform’ for INO, as published in its report on May 11, 2022. BofA Securities’s report from January 21, 2022 suggests a price prediction of $10 for INO shares, giving the stock a ‘Neutral’ rating. Jefferies also rated the stock as ‘Hold’.
Analysis of Inovio Pharmaceuticals Inc (INO)
Further, the quarter-over-quarter decrease in sales is -17.66%, showing a negative trend in the upcoming months.
One of the most important indicators of Inovio Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -79.55% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.60, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and INO is recording 488.71K average volume. On a monthly basis, the volatility of the stock is set at 9.43%, whereas on a weekly basis, it is put at 11.61%, with a loss of -3.82% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.25, showing growth from the present price of $11.07, which can serve as yet another indication of whether INO is worth investing in or should be passed over.
How Do You Analyze Inovio Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.61%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 17.90% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
INO shares are owned by institutional investors to the tune of 17.90% at present.
